Trans Ova Genetics continues to Multiply Success for clients
July 5, 2022
Today, Precigen, Inc., the parent company of Trans Ova Genetics, L.C. (“Trans Ova”), announced a definitive agreement for the sale of Trans Ova to URUS. Consummation of the transaction, anticipated in Q3 2022, is subject to customary closing conditions, including clearance under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. Trans Ova is an industry-leading provider of bovine reproductive technologies. Trans Ova’s dedication and strong commitment to its clients, which has sustained its outstanding reputation in the industry, will continue unabated. Trans Ova will continue under the leadership of David Faber, D.V.M, CEO & President, and his current management team. URUS is…
Keep Reading